HRP20131081T1 - Kombinirane terapije koje sadrže hinoksalin inhibitor p13k-alfa za uporabu u lijeäśenju kancera - Google Patents
Kombinirane terapije koje sadrže hinoksalin inhibitor p13k-alfa za uporabu u lijeäśenju kancera Download PDFInfo
- Publication number
- HRP20131081T1 HRP20131081T1 HRP20131081AT HRP20131081T HRP20131081T1 HR P20131081 T1 HRP20131081 T1 HR P20131081T1 HR P20131081A T HRP20131081A T HR P20131081AT HR P20131081 T HRP20131081 T HR P20131081T HR P20131081 T1 HRP20131081 T1 HR P20131081T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- chemotherapeutic agent
- compound according
- treatment
- small cell
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 8
- 201000011510 cancer Diseases 0.000 title claims 8
- 238000011282 treatment Methods 0.000 title claims 7
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 title 2
- 238000002648 combination therapy Methods 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 claims 13
- 229940127089 cytotoxic agent Drugs 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 11
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 3
- 229960001433 erlotinib Drugs 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 3
- 229960002930 sirolimus Drugs 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical group [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 125000002456 taxol group Chemical group 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (11)
1. Spoj koji je:
[image]
ili njegov pojedinačni izomer ili tautomer gdje je spoj izborno kao njegova farmaceutski prihvatljiva sol i dodatno izborno kao hidrat i dodatno izborno kao solvat; za uporabu u kombinaciji sa jednim ili više tretmana nezavisno izabranih od jednog ili više kemoterapeutskih sredstavaizabranih iz grupe koju čine platin, taksan, rapamicin i erlotinib za liječenje kancera.
2. Spojili njegov pojedinačni izomer ili tautomer prema patentnom zahtjevu 1, naznačen time što je kancer izabran iz grupe koju čine kancer dojke, kancer debelog crijeva, kancer rektuma, kancer endometrija, gastrointestinalni karcinoidni tumori, gastrointestinalni stromalni tumori, glioblastom, hepatostanični karcinom, sitnostanični kancer pluća, nesitnostanični kancer pluća, melanom, kancer jajnika, kancer grlića materice, kancer pankreasa, karcinom prostate, akutna mijelogena leukemija, kronična mijelogena leukemija, ne-Hodgkinov limfom i karcinom tireoidee.
3. Spoj prema patentnom zahtjevu 1, naznačen time što je tretman jedno kemoterapeutsko sredstvo, gdje je kemoterapeutsko sredstvo taksol.
4. Spoj prema patentnom zahtjevu 1, naznačen time što je tretman jedno kemoterapeutsko sredstvo, gdje je kemoterapeutsko sredstvo rapamicin.
5. Spoj prema patentnom zahtjevu 1, naznačen time što je tretman jedno kemoterapeutsko sredstvo, gdje je kemoterapeutsko sredstvo karboplatin.
6. Spoj prema patentnom zahtjevu 1, naznačen time što je tretman jedno kemoterapeutsko sredstvo, gdje je kemoterapeutsko sredstvo erlotinib.
7. Spoj prema patentnom zahtjevu 1, naznačen time što je kancer izabran od kancera prostate, nesitnostaničnog kancera pluća i kancera dojke.
8. Spoj prema patentnom zahtjevu 1, naznačen time što je kemoterapeutsko sredstvo taksol i kancer je kancer prostate.
9. Spoj prema patentnom zahtjevu 1, naznačen time što je kemoterapeutsko sredstvo rapamicin i kancer je kancer prostate.
10. Spoj prema patentnom zahtjevu 1, naznačen time što je kemoterapeutsko sredstvo karboplatin i kancer je nesitnostanični kancer pluća.
11. Spoj prema patentnom zahtjevu 1, naznačen time što je kemoterapeutsko sredstvo erlotinib i kancer je kancer dojke.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92316407P | 2007-04-11 | 2007-04-11 | |
| PCT/US2008/004570 WO2008127594A2 (en) | 2007-04-11 | 2008-04-08 | Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20131081T1 true HRP20131081T1 (hr) | 2013-12-20 |
Family
ID=39864581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20131081AT HRP20131081T1 (hr) | 2007-04-11 | 2013-11-12 | Kombinirane terapije koje sadrže hinoksalin inhibitor p13k-alfa za uporabu u lijeäśenju kancera |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US8481001B2 (hr) |
| EP (1) | EP2139483B9 (hr) |
| JP (2) | JP5726515B2 (hr) |
| KR (1) | KR101586774B1 (hr) |
| CN (2) | CN101959516B (hr) |
| AU (1) | AU2008239668B2 (hr) |
| BR (1) | BRPI0810208A2 (hr) |
| CA (1) | CA2684056A1 (hr) |
| CO (1) | CO6140024A2 (hr) |
| CR (1) | CR11099A (hr) |
| CY (1) | CY1114608T1 (hr) |
| DK (1) | DK2139483T3 (hr) |
| EA (1) | EA019064B1 (hr) |
| EC (1) | ECSP099723A (hr) |
| ES (1) | ES2438998T3 (hr) |
| GT (1) | GT200900263A (hr) |
| HK (1) | HK1140141A1 (hr) |
| HR (1) | HRP20131081T1 (hr) |
| IL (1) | IL201211A (hr) |
| MA (1) | MA31335B1 (hr) |
| ME (1) | ME00937B (hr) |
| MX (1) | MX2009010929A (hr) |
| MY (1) | MY150797A (hr) |
| NI (1) | NI200900184A (hr) |
| NZ (1) | NZ580009A (hr) |
| PL (1) | PL2139483T3 (hr) |
| PT (1) | PT2139483E (hr) |
| RS (1) | RS53020B (hr) |
| SI (1) | SI2139483T1 (hr) |
| SV (1) | SV2009003390A (hr) |
| TN (1) | TN2009000399A1 (hr) |
| UA (1) | UA98141C2 (hr) |
| WO (1) | WO2008127594A2 (hr) |
| ZA (1) | ZA200906765B (hr) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101395155A (zh) * | 2005-10-07 | 2009-03-25 | 埃克塞里艾克西斯公司 | PI3Kα的吡啶并嘧啶酮抑制剂 |
| JP5270353B2 (ja) * | 2005-10-07 | 2013-08-21 | エクセリクシス， インク． | ホスファチジルイノシトール３−キナーゼインヒビターとその使用方法 |
| EP2056829B9 (en) | 2006-08-16 | 2012-09-26 | Exelixis, Inc. | Using pi3k and mek modulators in treatments of cancer |
| EP2139484B9 (en) * | 2007-04-10 | 2014-06-11 | Exelixis, Inc. | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha |
| PL2374802T3 (pl) | 2008-11-10 | 2014-09-30 | Kyowa Hakko Kirin Co Ltd | Inhibitor wytwarzania kinureniny |
| DE102009049679A1 (de) | 2009-10-19 | 2011-04-21 | Merck Patent Gmbh | Pyrazolopyrimidinderivate |
| US8901137B2 (en) | 2010-02-09 | 2014-12-02 | Exelixis, Inc. | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors |
| AU2011274510A1 (en) | 2010-07-09 | 2013-01-24 | Exelixis, Inc. | Combinations of kinase inhibitors for the treatment of cancer |
| WO2012037204A1 (en) | 2010-09-14 | 2012-03-22 | Exelixis, Inc. | Inhibitors of pi3k-delta and methods of their use and manufacture |
| KR20130141528A (ko) | 2010-10-20 | 2013-12-26 | 메르크 세로노 에스에이 제네바 | 치환 ｎ-(3-아미노-퀴녹살린-2-일)-술폰아미드 및 이들의 중간체인 ｎ-(3-클로로-퀴녹살린-2-일)술폰아미드의 제조 방법 |
| DE102010048800A1 (de) * | 2010-10-20 | 2012-05-10 | Merck Patent Gmbh | Chinoxalinderivate |
| DE102010049595A1 (de) | 2010-10-26 | 2012-04-26 | Merck Patent Gmbh | Chinazolinderivate |
| WO2012065057A2 (en) | 2010-11-12 | 2012-05-18 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors and methods of their use |
| UY34339A (es) * | 2011-09-14 | 2013-04-30 | Exelixis Inc | Inhibidores de la fosfatidilinositol 3-quinasa para el tratamiento del cancer |
| WO2013052699A2 (en) * | 2011-10-04 | 2013-04-11 | Gilead Calistoga Llc | Novel quinoxaline inhibitors of pi3k |
| WO2013056067A1 (en) | 2011-10-13 | 2013-04-18 | Exelixis, Inc. | Compounds for use in the treatment of basal cell carcinoma |
| WO2013063000A1 (en) * | 2011-10-28 | 2013-05-02 | Novartis Ag | Method of treating gastrointestinal stromal tumors |
| BR112014010492A2 (pt) * | 2011-11-01 | 2017-04-25 | Exelixis Inc | n-(3-{[(3-{[2-cloro-5-(metóxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilalaninamida como inibidor de fosfatidilinositol 3-cinase para o tratamento de malignidades linfoproliferativas |
| WO2013067306A1 (en) * | 2011-11-02 | 2013-05-10 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors for the treatment of childhood cancers |
| US20150010545A1 (en) * | 2011-12-27 | 2015-01-08 | Kadmon Corporation, Llc | Methods for treatment of breast cancer nonresponsive to trastuzumab |
| WO2013152717A1 (zh) | 2012-04-10 | 2013-10-17 | 上海昀怡健康管理咨询有限公司 | 稠合嘧啶类化合物，其制备方法，中间体，组合物和应用 |
| EP2882722B1 (en) | 2012-08-13 | 2016-07-27 | Takeda Pharmaceutical Company Limited | Quinoxaline derivatives as gpr6 modulators |
| US9745321B2 (en) | 2013-09-30 | 2017-08-29 | Shanghai Yingli Pharmaceutical Co., Ltd | Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof |
| SG11201602446VA (en) | 2013-10-16 | 2016-05-30 | Shanghai Yingli Pharm Co Ltd | Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof |
| EP3105230B1 (en) | 2014-02-14 | 2021-04-07 | Takeda Pharmaceutical Company Limited | Pyridopyrazines modulators of gpr6 |
| US9950194B2 (en) | 2014-09-09 | 2018-04-24 | Mevion Medical Systems, Inc. | Patient positioning system |
| WO2019119206A1 (en) * | 2017-12-18 | 2019-06-27 | Merck Sharp & Dohme Corp. | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004064734A2 (en) * | 2003-01-17 | 2004-08-05 | Threshold Pharmaceuticals, Inc. | Combination therapies for the treatment of cancer |
| EP1917252B1 (en) * | 2005-08-26 | 2014-01-01 | Merck Serono SA | Pyrazine derivatives and use as pi3k inhibitors |
| CN101395155A (zh) | 2005-10-07 | 2009-03-25 | 埃克塞里艾克西斯公司 | PI3Kα的吡啶并嘧啶酮抑制剂 |
| JP5270353B2 (ja) * | 2005-10-07 | 2013-08-21 | エクセリクシス， インク． | ホスファチジルイノシトール３−キナーゼインヒビターとその使用方法 |
| EP2056829B9 (en) | 2006-08-16 | 2012-09-26 | Exelixis, Inc. | Using pi3k and mek modulators in treatments of cancer |
| AU2008219297B2 (en) * | 2007-02-22 | 2013-07-04 | Merck Serono S.A. | Quinoxaline compounds and use thereof |
| EP2139484B9 (en) | 2007-04-10 | 2014-06-11 | Exelixis, Inc. | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha |
| JP4623164B2 (ja) * | 2008-08-21 | 2011-02-02 | セイコーエプソン株式会社 | プロジェクタ |
-
2008
- 2008-04-08 US US12/595,236 patent/US8481001B2/en active Active
- 2008-04-08 MX MX2009010929A patent/MX2009010929A/es active IP Right Grant
- 2008-04-08 PT PT87426748T patent/PT2139483E/pt unknown
- 2008-04-08 EA EA200970935A patent/EA019064B1/ru not_active IP Right Cessation
- 2008-04-08 CN CN2008800173944A patent/CN101959516B/zh not_active Expired - Fee Related
- 2008-04-08 EP EP08742674.8A patent/EP2139483B9/en active Active
- 2008-04-08 DK DK08742674.8T patent/DK2139483T3/da active
- 2008-04-08 WO PCT/US2008/004570 patent/WO2008127594A2/en active Application Filing
- 2008-04-08 ME MEP-2009-304A patent/ME00937B/me unknown
- 2008-04-08 SI SI200831061T patent/SI2139483T1/sl unknown
- 2008-04-08 UA UAA200911452A patent/UA98141C2/ru unknown
- 2008-04-08 KR KR1020097023536A patent/KR101586774B1/ko active IP Right Grant
- 2008-04-08 MY MYPI20094215 patent/MY150797A/en unknown
- 2008-04-08 CN CN2013101161222A patent/CN103202842A/zh active Pending
- 2008-04-08 CA CA002684056A patent/CA2684056A1/en not_active Abandoned
- 2008-04-08 JP JP2010503043A patent/JP5726515B2/ja active Active
- 2008-04-08 AU AU2008239668A patent/AU2008239668B2/en not_active Ceased
- 2008-04-08 PL PL08742674T patent/PL2139483T3/pl unknown
- 2008-04-08 RS RS20130486A patent/RS53020B/en unknown
- 2008-04-08 BR BRPI0810208-2A2A patent/BRPI0810208A2/pt not_active IP Right Cessation
- 2008-04-08 NZ NZ580009A patent/NZ580009A/xx not_active IP Right Cessation
- 2008-04-08 ES ES08742674.8T patent/ES2438998T3/es active Active
-
2009
- 2009-09-29 IL IL201211A patent/IL201211A/en active IP Right Grant
- 2009-09-29 ZA ZA200906765A patent/ZA200906765B/xx unknown
- 2009-09-30 TN TNP2009000399A patent/TN2009000399A1/fr unknown
- 2009-10-09 GT GT200900263A patent/GT200900263A/es unknown
- 2009-10-09 NI NI200900184A patent/NI200900184A/es unknown
- 2009-10-09 SV SV2009003390A patent/SV2009003390A/es unknown
- 2009-10-30 MA MA32313A patent/MA31335B1/fr unknown
- 2009-11-09 CO CO09126923A patent/CO6140024A2/es unknown
- 2009-11-09 CR CR11099A patent/CR11099A/es unknown
- 2009-11-09 EC EC2009009723A patent/ECSP099723A/es unknown
-
2010
- 2010-07-05 HK HK10106504.4A patent/HK1140141A1/xx not_active IP Right Cessation
-
2013
- 2013-11-01 JP JP2013228684A patent/JP2014074031A/ja active Pending
- 2013-11-12 HR HRP20131081AT patent/HRP20131081T1/hr unknown
- 2013-11-15 CY CY20131101016T patent/CY1114608T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20131081T1 (hr) | Kombinirane terapije koje sadrže hinoksalin inhibitor p13k-alfa za uporabu u lijeäśenju kancera | |
| JP2010523670A5 (hr) | ||
| JP2014034576A5 (hr) | ||
| JP2018140982A5 (hr) | ||
| AR085718A1 (es) | Sales de 2,3-dihidroimidazo[1,2-c]quinazolina substituida | |
| HRP20161074T1 (hr) | Benzoksazolski inhibitori kinaza i postupci njihove upotrebe | |
| IL201284A (en) | K3pi alpha pyridopyrimidinone inhibitor for use in combination with one or more therapeutic agents selected from Taxol, Rapamycin, Carboplatin and Arlutinib for cancer treatment | |
| JP2008524329A5 (hr) | ||
| JP2009514880A5 (hr) | ||
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| JP2009514881A5 (hr) | ||
| EA201492004A1 (ru) | Органические композиции для лечения kras-ассоциированных заболеваний | |
| AR074575A1 (es) | Compuesto de benzoimidazol-pirimidin-aminopiridina, forma cristalina iii relacionada, formulacion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un cancer | |
| CL2011001863A1 (es) | Compuestos derivados de fenilaminopirimidinas, inhibidores de quinasa del linfoma anaplastico; composicion farmaceutica; combinacion farmacologica; y su uso en el tratamiento de trastornos proliferativos tales como linfoma, osteosarcoma, melanoma o tumor de mama, renal y de prostata, entre otros (divisional solicitud 3552-07). | |
| IL266563B (en) | Heterocyclic compounds used as pdk1 inhibitors | |
| RU2018100142A (ru) | Гетероциклические соединения, эффективные для ингибирования киназы | |
| JP2016520528A5 (hr) | ||
| JP2010507577A5 (hr) | ||
| RU2015143437A (ru) | Способы лечения рака и предотвращения устойчивости к лекарственным препаратам для лечения рака | |
| JP2014526450A5 (hr) | ||
| NZ596365A (en) | Pentamidine combinations for treating cancer | |
| TN2012000110A1 (en) | N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer | |
| JP2014518544A5 (hr) | ||
| JP2013523843A5 (hr) | ||
| JP2008527038A5 (hr) |